Increased Demand Drives Queensland Compound Library Expansion
News Jun 10, 2010
Queensland Compound Library (QCL) has announced the acquisition and installment of a fourth comPOUND® sample store from TTP LabTech Ltd.
The purchasing of a fourth sample store, to integrate with their three existing comPOUND sample stores and comPANION unit, comes two years after QCL became operational and one year after the third store was added. This new purchase reflects the on-going success of QCL and the increased demand for compound management and logistics services now considered essential by the Australian life sciences industry, QCL said.
TTP LabTech’s comPOUND sample store is a modular system, where individual units can be linked in parallel in response to growing library size. The self-contained modules each have their own cherry picking facility and can provide sample storage at a user defined temperature between ambient and -20°C depending on the user’s requirements.
The comPANION arrayer unit connects comPOUND stores to provide remote delivery or storage of individual microtubes from each of the sample stores.
Dr David Camp of QCL commented, ‘More than 300,000 compounds have been deposited by QCL members since mid 2008 which has necessitated the purchase of our fourth comPOUND sample store. Fortunately, the system is easily expanded to cater for increased demand. This has been the second comPOUND to be added since the QCL was established. The installation went seamlessly with full integration of the new module achieved mid-way through the second day. Sample processing was up and running by the third day, breaking the previous record set by the 3rd store which is not only good for the QCL but also for its members.”
Dr Camp went on saying, “Our members are from different organizations with vastly different needs. The QCL must cater for everything from open access samples to very limited access samples. The comPOUND sample store and our in-house checks allow us to use samples as intended.’
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE